Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer
Primary Sponsor
ANZUP
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
800
Final Accrual
802
Closing Date of Accrual
30 June 2018
Trial Contact
enzarad.study@sydney.edu.au
Related Post
14 April, 2026
Consumer Engagement Charter cements TROG’s commitment to listen to consumer voices
LATEST NEWS: 14 April 2026 TROG has made a
9 April, 2026
Vale Professor Jim Denham OAM, TROG founder and world-class researcher
9 April 2026 TROG Cancer Research honours the life